Hai‐Yan Tu
About
Hai‐Yan Tu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Hai‐Yan Tu has authored 114 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Pulmonary and Respiratory Medicine, 72 papers in Oncology and 26 papers in Cancer Research. Recurrent topics in Hai‐Yan Tu's work include Lung Cancer Treatments and Mutations (85 papers), Lung Cancer Research Studies (29 papers) and Colorectal Cancer Treatments and Studies (25 papers). Hai‐Yan Tu is often cited by papers focused on Lung Cancer Treatments and Mutations (85 papers), Lung Cancer Research Studies (29 papers) and Colorectal Cancer Treatments and Studies (25 papers). Hai‐Yan Tu collaborates with scholars based in China, United States and Germany. Hai‐Yan Tu's co-authors include Yi‐Long Wu, Qing Zhou, Jin‐Ji Yang, Jian Su, Wen‐Zhao Zhong, Hong‐Hong Yan, Xu‐Chao Zhang, Zhi Xie, Zhong‐Yi Dong and Li‐Xu Yan and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Cell.
In The Last Decade
Hai‐Yan Tu
102 papers receiving 3.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hai‐Yan Tu China | 23 | 2.4k | 2.2k | 716 | 695 | 332 | 114 | 3.1k | ||
| Davey B. Daniel United States | 19 | 2.1k 0.9× | 2.2k 1.0× | 688 1.0× | 538 0.8× | 362 1.1× | 82 | 3.3k | ||
| Hong‐Hong Yan China | 31 | 2.8k 1.2× | 2.5k 1.1× | 866 1.2× | 870 1.3× | 223 0.7× | 133 | 3.7k | ||
| Venice Archer United Kingdom | 9 | 3.6k 1.5× | 3.6k 1.6× | 663 0.9× | 919 1.3× | 276 0.8× | 16 | 4.6k | ||
| Shelley Coleman United States | 7 | 1.9k 0.8× | 2.8k 1.2× | 387 0.5× | 399 0.6× | 599 1.8× | 10 | 3.2k | ||
| Willemijn S.M.E. Theelen Netherlands | 16 | 3.3k 1.4× | 3.0k 1.4× | 873 1.2× | 998 1.4× | 385 1.2× | 33 | 4.4k | ||
| Liza C. Villaruz United States | 23 | 1.2k 0.5× | 1.3k 0.6× | 422 0.6× | 675 1.0× | 228 0.7× | 81 | 2.0k | ||
| Chong‐Rui Xu China | 27 | 3.5k 1.5× | 3.1k 1.4× | 931 1.3× | 1.0k 1.5× | 202 0.6× | 122 | 4.4k | ||
| Tiziana Usari Italy | 17 | 3.5k 1.5× | 3.1k 1.4× | 1.0k 1.4× | 1.2k 1.8× | 235 0.7× | 51 | 4.4k | ||
| Michael McCleod United States | 17 | 1.7k 0.7× | 2.5k 1.1× | 276 0.4× | 410 0.6× | 341 1.0× | 44 | 3.0k | ||
| V.A. Miller United States | 22 | 1.6k 0.7× | 2.1k 0.9× | 508 0.7× | 924 1.3× | 218 0.7× | 83 | 3.0k |
Countries citing papers authored by Hai‐Yan Tu
Since
Specialization
Citations
This map shows the geographic impact of Hai‐Yan Tu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hai‐Yan Tu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hai‐Yan Tu more than expected).
Fields of papers citing papers by Hai‐Yan Tu
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Hai‐Yan Tu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hai‐Yan Tu. The network helps show where Hai‐Yan Tu may publish in the future.
Co-authorship network of co-authors of Hai‐Yan Tu
This figure shows the co-authorship network connecting the top 25 collaborators of Hai‐Yan Tu. A scholar is included among the top collaborators of Hai‐Yan Tu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hai‐Yan Tu. Hai‐Yan Tu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Tu, Hai‐Yan, et al.. (2025). Combined Effects of Donepezil and Memantine on Behavioral and Psychological Symptoms, Cognitive Function, and Daily Living Abilities in Patients With Alzheimer’s Disease. British Journal of Hospital Medicine. 86(6). 1–15.
2.
Heymach, John V., Frans L. Opdam, Minal Barve, et al.. (2025). HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study. Journal of Clinical Oncology. 43(11). 1337–1347.
3.
Heymach, John V., Myung‐Ju Ahn, Nicolas Girard, et al.. (2025). Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine. 392(23). 2321–2333.
4.
Chen, Huajun, Hai‐Yan Tu, Yanping Hu, et al.. (2025). A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001). Journal of Hematology & Oncology. 18(1). 3–3.
5.
Yamamoto, Noboru, Hai‐Yan Tu, M-J. Ahn, et al.. (2024). LBA5 Zongertinib in patients with HER2-mutant NSCLC: Updated analysis of beamion LUNG-1. Annals of Oncology. 35. S1623–S1624.
6.
Zheng, Mei-Mei, Qing Zhou, Ben‐Yuan Jiang, et al.. (2024). Cerebrospinal fluid circulating tumour DNA profiling for risk stratification and matched treatment for central nervous system metastases of NSCLCM metastases of NSCLC. 5. 100175–100175.
7.
Berz, David, John V. Heymach, Frans L. Opdam, et al.. (2024). Beamion LUNG-1, a Phase Ia/Ib trial of the HER2-specific tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with HER2-driven tumors: outcomes according to HER2 aberration type. American Journal of Clinical Pathology. 162(Supplement_1). S127–S127.
8.
Zhou, Qing, Jie Li, Shundong Cang, et al.. (2024). FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation. Clinical Lung Cancer. 26(2). 152–157.e1.
9.
Liu, Si‐Yang Maggie, Jie Huang, Jia‐Yi Deng, et al.. (2023). PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial. Science Bulletin. 69(4). 535–543.
10.
Su, Junwei, Zhi Xie, Hanmin Wang, et al.. (2022). Clinical outcomes of EGFR +/METamp + vs. EGFR +/METamp ‐ untreated patients with advanced non‐small cell lung cancer. Thoracic Cancer. 13(11). 1619–1630.
11.
Zheng, Mei-Mei, Hai‐Yan Tu, Jin‐Ji Yang, et al.. (2021). Clinical outcomes of non–small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. European Journal of Cancer. 150. 23–30.
12.
Zhou, Qing, Chong‐Rui Xu, Ying Cheng, et al.. (2021). Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell. 39(9). 1279–1291.e3.
13.
Passaro, Antonio, Filippo de Marinis, Hai‐Yan Tu, et al.. (2021). Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. Frontiers in Oncology. 11. 709877–709877.
14.
Cui, Jiuwei, Qing Zhou, Shun Lü, et al.. (2021). The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment options. Translational Lung Cancer Research. 10(8). 3594–3607.
15.
Zheng, Mei-Mei, Yang-Si Li, Hai‐Yan Tu, et al.. (2020). Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC. Journal of Thoracic Oncology. 16(2). 250–258.
16.
Zheng, Mei-Mei, Yang-Si Li, Ben‐Yuan Jiang, et al.. (2019). Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC. Journal of Thoracic Oncology. 14(5). 924–932.
17.
Kang, Jin‐Hyoung, Hua‐Jun Chen, Xu‐Chao Zhang, et al.. (2018). Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer. Thoracic Cancer. 9(9). 1093–1103.
18.
Tu, Hai‐Yan, Yichen Zhang, & Yi‐Long Wu. (2017). A story of ALK variants and the efficacy of ALK inhibitors: moving toward precision oncology. Translational Cancer Research. 6(2).
19.
Huang, Shu‐Mei, Si-Pei Wu, Ri-Qiang Liao, et al.. (2017). P2.03b-043 Peripheral Blood CD45RA+ CCR7+ Naive T Cells Were Correlated with Prognosis in Non-Small Cell Lung Cancer Patients. Journal of Thoracic Oncology. 12(1). S961–S962.
20.
Dong, Zhong‐Yi, Wen‐Zhao Zhong, Xu‐Chao Zhang, et al.. (2016). Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clinical Cancer Research. 23(12). 3012–3024.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Davey B. Daniel Breakdown of academic impact, for papers by Hong‐Hong Yan Breakdown of academic impact, for papers by Venice Archer Breakdown of academic impact, for papers by Shelley Coleman Breakdown of academic impact, for papers by Willemijn S.M.E. Theelen Breakdown of academic impact, for papers by Liza C. Villaruz Breakdown of academic impact, for papers by Chong‐Rui Xu Breakdown of academic impact, for papers by Tiziana Usari Breakdown of academic impact, for papers by Michael McCleod Breakdown of academic impact, for papers by V.A. Miller